Author

Beatriz Sicilia Aladrén

SWITCHING FROM AN INTENSIFIED REGIMEN OF INFLIXIMAB TO A SUBCUTANEOUS STANDARD DOSE IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: OUR EXPERIENCE IN A TERTIARY HOSPITAL
SWITCHING FROM AN INTENSIFIED REGIMEN OF INFLIXIMAB TO A SUBCUTANEOUS STANDARD DOSE IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: OUR EXPERIENCE IN A TERTIARY HOSPITAL

ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY
ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY

Beatriz Sicilia Aladrén  et al.

SWITCHING FROM AN INTENSIFIED REGIMEN OF INFLIXIMAB TO A SUBCUTANEOUS STANDARD DOSE IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: OUR EXPERIENCE IN A TERTIARY HOSPITAL
SWITCHING FROM AN INTENSIFIED REGIMEN OF INFLIXIMAB TO A SUBCUTANEOUS STANDARD DOSE IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: OUR EXPERIENCE IN A TERTIARY HOSPITAL

Beatriz Sicilia Aladrén  et al.

GASTRIC CANCER MISSED IN A WELL-DEFINED SPANISH POPULATION
GASTRIC CANCER MISSED IN A WELL-DEFINED SPANISH POPULATION

Beatriz Sicilia Aladrén  et al.

REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY
REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY

Beatriz Sicilia Aladrén  et al.

IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY
IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY

Beatriz Sicilia Aladrén  et al.

REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY
REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY

Beatriz Sicilia Aladrén  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Beatriz Sicilia Aladrén  et al.

SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Beatriz Sicilia Aladrén  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Beatriz Sicilia Aladrén  et al.

Item 1 - 10 / 10
1